JAZZ PHARMACEUTICALS PLC (JAZZ) Fundamental Analysis & Valuation

NASDAQ:JAZZ • IE00B4Q5ZN47

182.01 USD
-1.62 (-0.88%)
At close: Mar 6, 2026
182.3 USD
+0.29 (+0.16%)
After Hours: 3/6/2026, 8:27:54 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This JAZZ fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

JAZZ gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. There are concerns on the financial health of JAZZ while its profitability can be described as average. JAZZ is cheap, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

6

1. JAZZ Profitability Analysis

1.1 Basic Checks

  • In the past year JAZZ was profitable.
  • JAZZ had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: JAZZ reported negative net income in multiple years.
  • JAZZ had a positive operating cash flow in 4 of the past 5 years.
JAZZ Yearly Net Income VS EBIT VS OCF VS FCFJAZZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

1.2 Ratios

  • JAZZ has a Return On Assets of -3.24%. This is in the better half of the industry: JAZZ outperforms 74.61% of its industry peers.
  • JAZZ's Return On Equity of -9.31% is fine compared to the rest of the industry. JAZZ outperforms 75.65% of its industry peers.
  • The Return On Invested Capital of JAZZ (3.95%) is better than 82.38% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for JAZZ is significantly below the industry average of 13.00%.
  • The 3 year average ROIC (3.85%) for JAZZ is below the current ROIC(3.95%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA -3.24%
ROE -9.31%
ROIC 3.95%
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
JAZZ Yearly ROA, ROE, ROICJAZZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10 15 20

1.3 Margins

  • In the last couple of years the Profit Margin of JAZZ has declined.
  • JAZZ's Operating Margin of 10.92% is amongst the best of the industry. JAZZ outperforms 83.94% of its industry peers.
  • In the last couple of years the Operating Margin of JAZZ has declined.
  • JAZZ has a better Gross Margin (88.49%) than 91.19% of its industry peers.
  • JAZZ's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 10.92%
PM (TTM) N/A
GM 88.49%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
JAZZ Yearly Profit, Operating, Gross MarginsJAZZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. JAZZ Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), JAZZ is destroying value.
  • JAZZ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
JAZZ Yearly Shares OutstandingJAZZ Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
JAZZ Yearly Total Debt VS Total AssetsJAZZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

  • Based on the Altman-Z score of 1.63, we must say that JAZZ is in the distress zone and has some risk of bankruptcy.
  • JAZZ's Altman-Z score of 1.63 is fine compared to the rest of the industry. JAZZ outperforms 61.14% of its industry peers.
  • The Debt to FCF ratio of JAZZ is 4.33, which is a neutral value as it means it would take JAZZ, 4.33 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 4.33, JAZZ belongs to the top of the industry, outperforming 84.97% of the companies in the same industry.
  • JAZZ has a Debt/Equity ratio of 1.09. This is a high value indicating a heavy dependency on external financing.
  • With a Debt to Equity ratio value of 1.09, JAZZ is not doing good in the industry: 72.54% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.09
Debt/FCF 4.33
Altman-Z 1.63
ROIC/WACC0.56
WACC7.09%
JAZZ Yearly LT Debt VS Equity VS FCFJAZZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.3 Liquidity

  • A Current Ratio of 1.65 indicates that JAZZ should not have too much problems paying its short term obligations.
  • JAZZ's Current ratio of 1.65 is on the low side compared to the rest of the industry. JAZZ is outperformed by 66.84% of its industry peers.
  • A Quick Ratio of 1.44 indicates that JAZZ should not have too much problems paying its short term obligations.
  • The Quick ratio of JAZZ (1.44) is worse than 63.73% of its industry peers.
Industry RankSector Rank
Current Ratio 1.65
Quick Ratio 1.44
JAZZ Yearly Current Assets VS Current LiabilitesJAZZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. JAZZ Growth Analysis

3.1 Past

  • JAZZ shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -61.30%.
  • The Earnings Per Share has been decreasing by -8.04% on average over the past years.
EPS 1Y (TTM)-61.3%
EPS 3Y-14.52%
EPS 5Y-8.04%
EPS Q2Q%0.61%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.09%

3.2 Future

  • Based on estimates for the next years, JAZZ will show a very strong growth in Earnings Per Share. The EPS will grow by 31.81% on average per year.
  • JAZZ is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.16% yearly.
EPS Next Y204.02%
EPS Next 2Y75.53%
EPS Next 3Y49.05%
EPS Next 5Y31.81%
Revenue Next Year4.81%
Revenue Next 2Y6.23%
Revenue Next 3Y7.11%
Revenue Next 5Y7.16%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
JAZZ Yearly Revenue VS EstimatesJAZZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
JAZZ Yearly EPS VS EstimatesJAZZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

8

4. JAZZ Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 22.20, the valuation of JAZZ can be described as rather expensive.
  • Compared to the rest of the industry, the Price/Earnings ratio of JAZZ indicates a rather cheap valuation: JAZZ is cheaper than 80.31% of the companies listed in the same industry.
  • When comparing the Price/Earnings ratio of JAZZ to the average of the S&P500 Index (26.29), we can say JAZZ is valued inline with the index average.
  • With a Price/Forward Earnings ratio of 7.30, the valuation of JAZZ can be described as very cheap.
  • Based on the Price/Forward Earnings ratio, JAZZ is valued cheaply inside the industry as 93.26% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.57, JAZZ is valued rather cheaply.
Industry RankSector Rank
PE 22.2
Fwd PE 7.3
JAZZ Price Earnings VS Forward Price EarningsJAZZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • 84.97% of the companies in the same industry are more expensive than JAZZ, based on the Enterprise Value to EBITDA ratio.
  • JAZZ's Price/Free Cash Flow ratio is rather cheap when compared to the industry. JAZZ is cheaper than 91.71% of the companies in the same industry.
Industry RankSector Rank
P/FCF 9.04
EV/EBITDA 12.2
JAZZ Per share dataJAZZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 60

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of JAZZ may justify a higher PE ratio.
  • A more expensive valuation may be justified as JAZZ's earnings are expected to grow with 49.05% in the coming years.
PEG (NY)0.11
PEG (5Y)N/A
EPS Next 2Y75.53%
EPS Next 3Y49.05%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. JAZZ Dividend Analysis

5.1 Amount

  • JAZZ does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

JAZZ Fundamentals: All Metrics, Ratios and Statistics

JAZZ PHARMACEUTICALS PLC

NASDAQ:JAZZ (3/6/2026, 8:27:54 PM)

After market: 182.3 +0.29 (+0.16%)

182.01

-1.62 (-0.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-24
Earnings (Next)05-04
Inst Owners104.02%
Inst Owner Change0.46%
Ins Owners2.48%
Ins Owner Change-0.22%
Market Cap11.20B
Revenue(TTM)N/A
Net Income(TTM)-368.48M
Analysts85.22
Price Target223.78 (22.95%)
Short Float %10.17%
Short Ratio5.66
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.15%
Min EPS beat(2)-6.35%
Max EPS beat(2)34.65%
EPS beat(4)2
Avg EPS beat(4)-6.25%
Min EPS beat(4)-64.64%
Max EPS beat(4)34.65%
EPS beat(8)4
Avg EPS beat(8)-5.06%
EPS beat(12)4
Avg EPS beat(12)-14.55%
EPS beat(16)7
Avg EPS beat(16)-9.8%
Revenue beat(2)0
Avg Revenue beat(2)-1.26%
Min Revenue beat(2)-2.09%
Max Revenue beat(2)-0.43%
Revenue beat(4)1
Avg Revenue beat(4)-3.13%
Min Revenue beat(4)-10.66%
Max Revenue beat(4)0.66%
Revenue beat(8)1
Avg Revenue beat(8)-2.61%
Revenue beat(12)1
Avg Revenue beat(12)-2.27%
Revenue beat(16)3
Avg Revenue beat(16)-2.04%
PT rev (1m)1.29%
PT rev (3m)15.46%
EPS NQ rev (1m)1.72%
EPS NQ rev (3m)1.53%
EPS NY rev (1m)1.18%
EPS NY rev (3m)54.77%
Revenue NQ rev (1m)0.76%
Revenue NQ rev (3m)1.02%
Revenue NY rev (1m)0.19%
Revenue NY rev (3m)0.42%
Valuation
Industry RankSector Rank
PE 22.2
Fwd PE 7.3
P/S 2.69
P/FCF 9.04
P/OCF 8.05
P/B 2.83
P/tB N/A
EV/EBITDA 12.2
EPS(TTM)8.2
EY4.51%
EPS(NY)24.93
Fwd EY13.7%
FCF(TTM)20.13
FCFY11.06%
OCF(TTM)22.61
OCFY12.42%
SpS67.54
BVpS64.31
TBVpS-39.54
PEG (NY)0.11
PEG (5Y)N/A
Graham Number108.93
Profitability
Industry RankSector Rank
ROA -3.24%
ROE -9.31%
ROCE 5%
ROIC 3.95%
ROICexc 5.1%
ROICexgc 55.75%
OM 10.92%
PM (TTM) N/A
GM 88.49%
FCFM 29.8%
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
ROICexc(3y)4.89%
ROICexc(5y)5.68%
ROICexgc(3y)31.42%
ROICexgc(5y)35.77%
ROCE(3y)4.87%
ROCE(5y)5.36%
ROICexgc growth 3Y32.25%
ROICexgc growth 5Y-7.79%
ROICexc growth 3Y35.45%
ROICexc growth 5Y-6.86%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
F-Score5
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 1.09
Debt/FCF 4.33
Debt/EBITDA 3.8
Cap/Depr 22.29%
Cap/Sales 3.68%
Interest Coverage 250
Cash Conversion 122.16%
Profit Quality N/A
Current Ratio 1.65
Quick Ratio 1.44
Altman-Z 1.63
F-Score5
WACC7.09%
ROIC/WACC0.56
Cap/Depr(3y)31.05%
Cap/Depr(5y)47.54%
Cap/Sales(3y)5.31%
Cap/Sales(5y)6.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-61.3%
EPS 3Y-14.52%
EPS 5Y-8.04%
EPS Q2Q%0.61%
EPS Next Y204.02%
EPS Next 2Y75.53%
EPS Next 3Y49.05%
EPS Next 5Y31.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.09%
Revenue Next Year4.81%
Revenue Next 2Y6.23%
Revenue Next 3Y7.11%
Revenue Next 5Y7.16%
EBIT growth 1Y-35.5%
EBIT growth 3Y22.09%
EBIT growth 5Y6.42%
EBIT Next Year-57.5%
EBIT Next 3Y6.55%
EBIT Next 5Y7.24%
FCF growth 1Y42.84%
FCF growth 3Y22.51%
FCF growth 5Y17.8%
OCF growth 1Y9.88%
OCF growth 3Y21.49%
OCF growth 5Y12.45%

JAZZ PHARMACEUTICALS PLC / JAZZ FAQ

Can you provide the ChartMill fundamental rating for JAZZ PHARMACEUTICALS PLC?

ChartMill assigns a fundamental rating of 4 / 10 to JAZZ.


Can you provide the valuation status for JAZZ PHARMACEUTICALS PLC?

ChartMill assigns a valuation rating of 8 / 10 to JAZZ PHARMACEUTICALS PLC (JAZZ). This can be considered as Undervalued.


Can you provide the profitability details for JAZZ PHARMACEUTICALS PLC?

JAZZ PHARMACEUTICALS PLC (JAZZ) has a profitability rating of 6 / 10.


Can you provide the financial health for JAZZ stock?

The financial health rating of JAZZ PHARMACEUTICALS PLC (JAZZ) is 3 / 10.


What is the expected EPS growth for JAZZ PHARMACEUTICALS PLC (JAZZ) stock?

The Earnings per Share (EPS) of JAZZ PHARMACEUTICALS PLC (JAZZ) is expected to grow by 204.02% in the next year.